Cancer Epigenetics Training (CET) Program
癌症表观遗传学培训 (CET) 计划
基本信息
- 批准号:10269565
- 负责人:
- 金额:$ 14.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-05 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
This proposal seeks to develop a dedicated Cancer Epigenetics Training (CET) program at Van Andel
Research Institute (VARI) to train two new postdoctoral fellows per year for three years each. The objective
of the CET is to prepare 10 postdoctoral fellows to become independent academic and industry research
leaders in the field of cancer epigenetics. The CET program will build upon the Center for Epigenetics that
was established in 2014 by Peter Jones, Ph.D., D.Sc. (hon) and has grown into a world-class, internationally
recognized center of excellence for basic and translational epigenetics research. To launch the CET program,
we have assembled a team of 9 mentors and 6 co-mentors who collectively hold ~$5.7M of funding per year
and have highly complementary and interdisciplinary cancer and epigenetics expertise. CET faculty include
several epigenetics pioneers; two members of the National Academy of Sciences; the Van Andel Institute
Stand Up to Cancer Epigenetics Dream Team (VAI-SU2C); two leaders of The Cancer Genome Atlas (TCGA)
project; and mentors/co-mentors from all career stages. Trainees will be able to pursue basic and translational
research projects in cancer biology; tumorigenesis, cellular development and differentiation; mechanisms
governing DNA methylation and chromatin regulation; epigenomics and advanced tool development; GWAS
and EWAS; transgenerational inheritance; structural biology; metabolism; and epigenetic therapies. The CET
program is overseen by a dedicated Advisory Committee composed of domain-level experts from academic,
industrial, and clinical careers. We have developed a targeted diversity and recruitment plan to increase the
T32-eligible pool size and attract and retain individuals from underrepresented groups. Upon acceptance,
each Trainee is assigned an Individual Development Team (IDT) to coach, mentor, and guide the Trainee
through the scientific and non-scientific dimensions of career development. The faculty and CET Trainees are
supported by a dedicated Office of Postdoctoral Affairs that is directed by a PhD-level biomedical career
development professional. Each Trainee is required to complete a comprehensive curriculum of scientific and
professional development training. Key deliverables and milestones for T32 Trainees include annual seminars
(internal and external); at least one semester of teaching or mentoring experience; one first-authored
publication; and at least one submitted F32 (or equivalent) and K99/R00 application. The training
requirements and expectations are formalized within Individual Development Plans (IDPs) that are reviewed
annually by the Advisory Committee. Research-related, individualized training not otherwise defined in the
CET training program is provided by VARI. The CET will be rigorously evaluated through entrance, annual,
exit, and alumni assessments. With the superlative faculty, resources, and guidance afforded by the CET,
postdoctoral fellows will emerge with a comprehensive, multi-disciplinary skill set, perspective, and foundation
from which to establish their independent research careers in cancer epigenetics.
项目总结
这项提议寻求在Van Andel开发一个专门的癌症表观遗传学培训(CET)计划
研究所(VARI)每年培训两名新的博士后研究员,每名为期三年。目标是
CET的目的是培养10名博士后研究员,以成为独立的学术和行业研究人员
癌症表观遗传学领域的领导者。CET计划将建立在表观遗传学中心的基础上
是由彼得·琼斯博士于2014年创立的。已经成长为世界级的,国际上的
公认的基础和转化表遗传学研究的卓越中心。为了启动CET计划,
我们已经组建了一个由9名导师和6名共同导师组成的团队,他们每年总共拥有约570万美元的资金
并具有高度互补性和跨学科的癌症和表观遗传学专业知识。CET教师包括
几位表观遗传学先驱;美国国家科学院的两名成员;范安德尔研究所
对抗癌症表观遗传学梦想团队(VAI-SU2C);癌症基因组图谱(TCGA)的两名负责人
项目;以及职业生涯各个阶段的导师/共同导师。学员将能够学习基础知识和翻译知识
癌症生物学研究项目;肿瘤发生、细胞发育和分化;机制
管理DNA甲基化和染色质调节;表观基因组学和高级工具开发;
和EWAS;跨代遗传;结构生物学;新陈代谢;表观遗传疗法。大学英语四级考试
该计划由一个专门的咨询委员会监督,该委员会由来自学术界、
工业和临床职业。我们制定了有针对性的多元化和招聘计划,以增加
符合T32条件的人才库规模,并吸引和留住代表不足的群体中的个人。一经接受,
每个学员都被分配了一个单独的开发团队(IDT)来指导、指导和指导学员
通过职业发展的科学和非科学两个维度。教员和CET实习生是
由博士后事务办公室支持,该办公室由博士后级别的生物医学职业指导
开发专业人士。每个学员都必须完成科学和技术课程的综合课程
职业发展培训。T32学员的主要成果和里程碑包括年度研讨会
(内部和外部);至少一学期的教学或指导经验;一位第一作者
出版物;以及至少一份已提交的F32(或同等)和K99/R00申请。培训
要求和期望在经过审查的个人发展计划(IDP)中正式确定
咨询委员会每年举行一次会议。与研究相关的个性化培训没有在
CET培训项目由VARI提供。大学英语四级考试将通过入学、年度、
离职,以及校友评估。在CET提供的最好的师资、资源和指导下,
博士后研究员将拥有全面的、多学科的技能、视角和基础
从中建立他们在癌症表观遗传学方面的独立研究生涯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER A JONES其他文献
PETER A JONES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER A JONES', 18)}}的其他基金
Cancer Epigenetics Training (CET) Program
癌症表观遗传学培训 (CET) 计划
- 批准号:
10646461 - 财政年份:2021
- 资助金额:
$ 14.39万 - 项目类别:
Cancer Epigenetics Training (CET) Program
癌症表观遗传学培训 (CET) 计划
- 批准号:
10445044 - 财政年份:2021
- 资助金额:
$ 14.39万 - 项目类别:
Targeting DNA Methylation and the Cancer Epigenome
靶向 DNA 甲基化和癌症表观基因组
- 批准号:
10541829 - 财政年份:2017
- 资助金额:
$ 14.39万 - 项目类别:
Establishing and Interpreting Abnormal DNA Methylation in Cancer
建立并解释癌症中的异常 DNA 甲基化
- 批准号:
10732031 - 财政年份:2017
- 资助金额:
$ 14.39万 - 项目类别:
Targeting DNA Methylation and the Cancer Epigenome
靶向 DNA 甲基化和癌症表观基因组
- 批准号:
10320866 - 财政年份:2017
- 资助金额:
$ 14.39万 - 项目类别:
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
南加州大学/诺里斯综合癌症中心(核心)支持
- 批准号:
7930202 - 财政年份:2009
- 资助金额:
$ 14.39万 - 项目类别:
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
南加州大学/诺里斯综合癌症中心(核心)支持
- 批准号:
7931719 - 财政年份:2009
- 资助金额:
$ 14.39万 - 项目类别:
相似海外基金
Molecular Epidemiological and pathological studies on the association between lipoprotein(a) and malignant neoplasms
脂蛋白(a)与恶性肿瘤关系的分子流行病学及病理学研究
- 批准号:
17K08718 - 财政年份:2017
- 资助金额:
$ 14.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrated analysis and detection of new therapeutic target aimed for improvement of prognosis in the patients with pancreatic malignant neoplasms
综合分析检测改善胰腺恶性肿瘤患者预后的新治疗靶点
- 批准号:
24501337 - 财政年份:2012
- 资助金额:
$ 14.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6116914 - 财政年份:1998
- 资助金额:
$ 14.39万 - 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6219852 - 财政年份:1998
- 资助金额:
$ 14.39万 - 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
- 批准号:
6278109 - 财政年份:1997
- 资助金额:
$ 14.39万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305338 - 财政年份:1996
- 资助金额:
$ 14.39万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305324 - 财政年份:1996
- 资助金额:
$ 14.39万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2451660 - 财政年份:1996
- 资助金额:
$ 14.39万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2451659 - 财政年份:1996
- 资助金额:
$ 14.39万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
- 批准号:
2305309 - 财政年份:1995
- 资助金额:
$ 14.39万 - 项目类别: